The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://lnkd.in/gBHNDEF3 #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
BSI Healthcare’s Post
More Relevant Posts
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the healthcare & life sciences sector, explores for our blog: https://lnkd.in/gBHNDEF3 #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://gag.gl/MSgksQ #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
Estrategista de Negócios | Especialista em Desenvolvimento de Lideranças e Negócios | Vendas | R&D | Indicadores Chave Business Strategist | Leadership and Business Development Specialist | Sales | R&D | Key Indicators
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://gag.gl/MSgksQ #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://gag.gl/MSgksQ #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://gag.gl/MSgksQ #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the healthcare & life sciences sector, explores for our blog: https://gag.gl/R9XyDH #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://gag.gl/MSgksQ #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://gag.gl/MSgksQ #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
Estrategista de Negócios | Especialista em Desenvolvimento de Lideranças e Negócios | Vendas | R&D | Indicadores Chave Business Strategist | Leadership and Business Development Specialist | Sales | R&D | Key Indicators
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the healthcare & life sciences sector, explores for our blog: https://gag.gl/R9XyDH #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
-
The pharmaceutical sector needs to reduce its emissions intensity by about 59% from 2015 levels if it wants to meet the targets laid out in the Paris Agreement international treaty on climate change. Manufacturers have the opportunity to rethink how they can reduce greenhouse gas (GHG) emissions and other key environmental considerations when they design, manufacture and distribute medicines. Having previously been focused on the efficacy of medicines and patient safety, the sector is now taking into account environmental factors across the medicine’s lifecycle. The challenge in balancing patient safety and medicine efficacy, with environmental considerations, requires a pool of expertise – to appropriately cover the lifecycle of the medicine – from production through to end patient usage to disposal. Courtney Soulsby, BSI's Global Director for the Healthcare & Life Sciences sector, explores for our blog: https://gag.gl/MSgksQ #Pharmaceuticals #HealthcareEmissions #PatientSafety #Medicines
To view or add a comment, sign in
-
Retired Sr.General Manager and Healthcare Head at BSI Group, India
1moReally good